Estrogens and skin biology
==========================

A number of studies have shown that estrogens have many important beneficial and protective roles in skin physiology (reviewed in [@b123-cia-2-283], [@b124-cia-2-283]). They have been shown to accelerate cutaneous wound healing ([@b5-cia-2-283]), while a significant number of women notice an improvement in inflammatory skin disorders such as psoriasis during pregnancy ([@b34-cia-2-283]; [@b15-cia-2-283]; [@b96-cia-2-283]). Estrogens also offer some degree of protection against skin photoaging ([@b135-cia-2-283]; [@b126-cia-2-283], [@b127-cia-2-283]) and epidemiological studies indicate that the mortality rates from both non-melanoma skin cancers ([@b135-cia-2-283]) and melanoma ([@b74-cia-2-283]) are significantly lower in women.

Many of the effects of estrogen on human skin are based on the changes that are seen in post-menopausal women, with a number of studies documenting the differences seen following the menopause, although there is also a variation in skin thickness during the menstrual cycle, with skin thickness lowest at the start of the menstrual cycle, when estrogen and progesterone levels are low, which then increases with the rising levels of estrogen ([@b36-cia-2-283]). Many women report a sudden onset of skin aging several months after menopausal symptoms begin. The menopause causes hypoestrogenism, accelerating age-related deterioration, which results in thinner skin, an increase in number and depth of wrinkles, increased skin dryness, and decreased skin firmness and elasticity ([@b18-cia-2-283]). Hormone replacement therapy (HRT) has been shown to increase epidermal hydration, skin elasticity, skin thickness ([@b102-cia-2-283]), and also reduces skin wrinkles ([@b90-cia-2-283]). Furthermore, the content and quality of collagen and the level of vascularization is enhanced ([@b16-cia-2-283]).

The epidermis
=============

Epidermal thinning is associated with aging, and topical estradiol has been shown to reduce epidermal thinning in aging skin and maintain skin thickness ([@b106-cia-2-283]). Recent studies have confirmed that administration of estradiol to gonadectomised mice increases epidermal thickness in both sexes ([@b10-cia-2-283]).

In women an increase in the mitotic activity of epidermal keratinocytes occurs in response to estrogens ([@b93-cia-2-283]). Furthermore, the stimulation of proliferation and DNA synthesis of human epidermal keratinocytes by estrogens has been demonstrated in vitro ([@b128-cia-2-283]; [@b57-cia-2-283]; [@b131-cia-2-283]) and cultured human epidermal keratinocytes have high affinity estrogen binding sites ([@b131-cia-2-283]). Specific antibodies for the two distinct intracellular estrogen receptors (ERα and ERβ) have shown that epidermal keratinocytes from human scalp skin of both sexes predominately express ERβ in situ ([@b125-cia-2-283]).

However, primary cultures of epidermal keratinocytes from female breast skin express both ERα and ERβ in vitro (see [Figure 1](#f1-cia-2-283){ref-type="fig"}).

Another study has demonstrated mRNA and protein for ERβ and not ERα is expressed in cultured human epidermal keratinocytes ([@b55-cia-2-283], [@b56-cia-2-283]), while a different group have shown that both ERα and ERβ are expressed in cultured human neonatal foreskin keratinocytes ([@b131-cia-2-283]). These differences may be due to differences in anatomical site, since the number of estrogen receptors has been shown to differ with anatomical site, with face skin homogenates having a greater number of receptors than breast or thigh skin ([@b47-cia-2-283]). A more recent study has shown that there are marked differences in the expression of the two estrogen receptors in human skin derived from different anatomical sites including scalp, breast and abdomen ([@b81-cia-2-283]); in contrast to scalp, which predominantly expresses ERβ ([@b125-cia-2-283]), breast skin predominantly expresses ERα in situ ([@b81-cia-2-283]).

Recently, it has been reported that 17β-estradiol conjugated with BSA can stimulate proliferation and DNA synthesis of cultured human keratinocytes ([@b57-cia-2-283]), suggesting that estradiol can stimulate cell proliferation via a cell membrane receptor. This is further supported by another group who demonstrated that incubation of cultured human epidermal keratinocytes with estradiol increased phosphorylation levels of ERK1 and ERK2 kinases within 15 minutes ([@b131-cia-2-283]).

A protective role for estrogens on the human epidermis may also exist since estradiol prevents apoptosis induced by hydrogen peroxide in cultured epidermal keratinocytes by promoting the expression of bcl-2 ([@b55-cia-2-283]). Furthermore, estradiol inhibits the production of chemokines involved in the attraction of macrophages, which are important in inflammation ([@b56-cia-2-283]).

The dermis
==========

Autoradiography following administration of systemic or topical estrogen has demonstrated that radio-labeled estradiol binds to dermal fibroblasts in rat and mouse skin ([@b119-cia-2-283]; [@b14-cia-2-283]). More recently, specific antibodies have demonstrated ERβ, but not ERα is expressed by dermal fibroblasts in the papillary dermis of human scalp skin in both sexes ([@b125-cia-2-283]), whereas primary cultures of human dermal fibroblasts from female skin have been shown to express both mRNA and protein for ERα and ERβ ([@b44-cia-2-283]). Although dermal fibroblasts co-express both estrogen receptors, immunocytochemistry showed some variation in their expression; ERβ was predominately nuclear, while ERα was expressed in both the cytoplasm and the nucleus. Furthermore, mRNA levels for ERβ were higher than levels of ERα. A later study by the same group has demonstrated that estradiol up-regulates the expression of ERβ in dermal fibroblasts cultured from postmenopausal women ([@b122-cia-2-283]), thereby altering the ratio of ERα to ERβ.

Estrogens have been shown to influence skin thickness by stimulating collagen synthesis, maturation and turnover in rats ([@b111-cia-2-283]) and female guinea pigs ([@b48-cia-2-283]). In mice, estrogen administration increased hyaluronic acid synthesis by 70% in two weeks ([@b113-cia-2-283]), leading to increased dermal water content. In wound healing models, estrogen reduces wound size and stimulates matrix deposition in both human and murine skin ([@b7-cia-2-283]; [@b5-cia-2-283]), highlighting the effects of estrogens on the dermal fibroblasts.

Estrogen is also believed to provide some protection against photoaging. Ultraviolet (UV)-B exposure is associated with up-regulation of matrix metalloproteinase (MMP) production, leading to an increase in collagen degradation and is also thought to decrease type I and type III collagen synthesis (reviewed in [@b11-cia-2-283]). [@b126-cia-2-283] demonstrated that ovariectomized rats exposed to UVB radiation display an increased formation of deep wrinkles, decreased skin elasticity and marked and advanced curling of dermal elastic fibers compared to rats with normal estrogen levels. Furthermore, the same authors demonstrated that in hairless mice ovariectomy alone decreases skin elasticity, with a further significant increase in skin sagging in the ovariectomized animals exposed to 12 weeks of UV-A irradiation and a significant increase in skin wrinkling following UV-B irradiation ([@b127-cia-2-283]). In each case this was associated with an increase in elastase activity. This led the authors to suggest that ovariectomy causes an increase in elastase mediated degradation of dermal elastic fibers with a subsequent reduction in skin elasticity, thus explaining the skin changes seen in post-menopausal women.

In vitro, murine dermal fibroblasts have been shown to increase collagen synthesis by 76% in response to estrogen ([@b51-cia-2-283]). Similarly, incubation of cultured human dermal fibroblasts with 17β-estradiol increased type I procollagen secretion ([@b114-cia-2-283]). This effect was reversed when estrogen was administered with TGF-β1 antibodies, suggesting that TGF-β1 may play a role in increasing collagen secretion in response to estrogen. Other authors have also demonstrated an increase in collagen biosynthesis in vitro in response to 17β-estradiol by measuring radio-labeled proline incorporation ([@b122-cia-2-283]).

The hair follicle
-----------------

Hair follicles have a built in rhythm of activity that results in the periodic regeneration of new hairs and the molting of old ones. This rhythm appears to be intrinsic, although it can be influenced by hormonal or other systemic factors. Estrogens significantly influence the hair cycle in a number of mammalian species by inhibiting hair growth (reviewed in [@b123-cia-2-283], [@b124-cia-2-283]; Ohnemus et al 2006). However, the effects of estrogens on the human hair cycle are less clear.

In contrast to the inhibition observed in other mammals, limited studies suggest that estrogens may have a stimulatory effect on human hair growth. During pregnancy there is an increase in the ratio of hair follicles in the growing phase of the cycle; after parturition, these follicles enter the resting phase, resulting in increased hair shedding and a transient thinning of the hair ([@b69-cia-2-283]). These events have been ascribed to the changes in the level of circulating estrogen during, and immediately following pregnancy. However, it is difficult to accredit this phenomenon entirely to the rise in plasma estrogen as several other hormones and growth factors that modulate hair growth are also altered at this time.

There is some limited trichogram data to suggest that estrogens decrease the resting phase and prolong the growing phase of the hair cycle, hence estrogens are used in the treatment of female pattern hair loss in some countries ([@b110-cia-2-283]). Further evidence for a stimulatory effect of estrogens on human hair growth comes from the treatment of women with tamoxifen which may result in scalp hair thinning or recession in some women ([@b39-cia-2-283]; [@b9-cia-2-283]). Likewise, a common treatment-related side effect of aromatase inhibitors, which inhibit the synthesis of estrogen, is scalp hair thinning in women ([@b20-cia-2-283]; [@b109-cia-2-283]).

Recent in vitro studies have shown that 17β-estradiol inhibits female scalp hair shaft elongation ([@b81-cia-2-283])*,* although stimulation occurs in hair follicles derived from frontotemporal male scalp ([@b26-cia-2-283]; [@b26-cia-2-283]). In addition, in female hair follicles the phytoestrogen, genistein inhibits hair shaft elongation to a similar extent as 17β-estradiol. Since genistein preferentially binds to ERβ, this opens the possibility that the inhibition of hair growth in response to 17β-estradiol may be mediated via ERβ rather than ERα ([@b81-cia-2-283]). Therefore the development of selective estrogen receptor ligands may provide important clinical applications for the prevention and treatment of disorders of hair growth.

Melanocytes and melanoma
========================

Chloasma is a common hyperpigmentation of the face seen in pregnant women, often accompanied by increased pigmentation in other areas including the areolae, linea alba and perineal skin, all of which usually fade following parturition ([@b62-cia-2-283]). Oral contraceptives containing estrogen can also result in hyperpigmentation of the face ([@b132-cia-2-283]) and ointments containing estrogen can produce intense pigmentation of the genitals, mammary areola and linea alba of the abdomen in male and female infants ([@b12-cia-2-283]).

The mean age of presentation of malignant melanoma in women is the early fifties, which correlates with the onset of the menopause ([@b35-cia-2-283]). Melanoma has traditionally been considered to be an estrogen receptor-positive tumor, whose prognosis is adversely affected by estrogen, whether during pregnancy or in association with the oral contraceptive pill or HRT. Recent evidence now disputes this and the relationship between estrogens and malignant melanoma remains controversial.

There is a significant lack of information in relation to HRT and melanoma and the use of steroid hormones in the management of melanoma is limited. Steroid hormone binding activity has been demonstrated in some human melanomas, but only a small percentage of melanomas respond to hormonal manipulation ([@b79-cia-2-283]). The relative expressions of the different estrogen receptors in malignant melanoma have yet to be explored, which may be of significance since alterations in the ratio of ERα and ERβ have been suggested in the development and progression of other cancers.

The menopause
=============

Post-menopausal skin has been shown to have increased dryness ([@b101-cia-2-283]), decreased elasticity ([@b49-cia-2-283]; [@b121-cia-2-283]), and increased wrinkling ([@b33-cia-2-283]). Indeed, many of the effects of estrogen on the human skin have been described based on the changes that are seen following the menopause. Estrogen receptor expression has been shown to be reduced following the menopause ([@b94-cia-2-283]; [@b82-cia-2-283]).

In postmenopausal women skin thickness decreases by 1.13% per postmenopausal year, with an associated decrease in collagen content (2% per post-menopausal year) ([@b16-cia-2-283]). The collagen content (types I and III) of skin is thought to decrease by as much as 30% in the first five years following the menopause ([@b17-cia-2-283]; [@b2-cia-2-283]). Interestingly, this decrease in skin collagen content parallels the reduction in bone mass seen in post-menopausal women ([@b16-cia-2-283]). The decrease in skin thickness and collagen content seen in elderly females appears to correlate more closely with the period of estrogen deficiency than with chronological age ([@b17-cia-2-283], [@b16-cia-2-283]; [@b2-cia-2-283]).

In contrast, another study has demonstrated a closer relationship between chronological age and reduction in skin collagen, than time since menopause ([@b22-cia-2-283]). However, for the patients in this study the time spent post-menopause was much shorter, therefore the long-term effects of estrogen deficiency may not have become apparent.

A difference in collagen subtypes has also been documented in post-menopausal women. When evaluated by immunohistochemistry, compared to pre-menopausal women, post-menopausal women demonstrate a decrease in collagen types I and III and a reduction in the typeIII/type I ratio within the dermis. Again this correlates more closely with period of estrogen deficiency than with chronological age ([@b2-cia-2-283]). Similar findings have been reported in the arcus tendineous fasciae pelvis, where the collagen type I and type I/type III ratio was decreased in postmenopausal women compared to premenopausal women ([@b75-cia-2-283]). Interestingly, despite these changes the total amount of collagen was not altered.

Hormone replacement therapy
===========================

Further understanding of estrogen effects on human skin is derived from comparisons between post-menopausal women taking estrogen replacement therapy and those who have not. An early study reported an increase in epidermal thickness in human female skin in response to six months of oral estrogens ([@b93-cia-2-283]). Although a different study did not demonstrate an increase in epidermal thickness, [@b70-cia-2-283] demonstrated an increased keratinocyte volume and more defined rete ridges in response to oral estrogen.

More recent studies have confirmed that topical estrogen increases epidermal thickness ([@b114-cia-2-283]; [@b88-cia-2-283]). Furthermore, [@b114-cia-2-283] demonstrated an increase in keratinocyte proliferation and epidermal thickness in response to only two weeks of topical estrogen in the skin of elderly males and females. HRT has also been shown to improve skin hydration when estrogen is administered systemically ([@b91-cia-2-283]) or topically ([@b102-cia-2-283]). Topical application is an efficient method, since due to its small molecular size; estrogen easily penetrates the stratum corneum ([@b32-cia-2-283]). The increased hydration is believed to be due in part to an increase in the water-holding capacity of the stratum corneum ([@b91-cia-2-283]). Additionally, dermal hyaluronic acid and acid mucopolysaccharide levels are increased, which will also improve hydration (reviewed in [@b106-cia-2-283]).

In a randomized, double-blind, placebo-controlled trial, [@b70-cia-2-283], demonstrated that after 12 months of oral estrogen therapy, dermal thickness was increased by 30%, resulting in increased skin thickness in post-menopausal nuns. Skin biopsies were taken from the thigh thus eliminating confounding factors such as sun exposure and smoking ([@b70-cia-2-283]). Other authors have also demonstrated increased skin thickness following HRT ([@b17-cia-2-283]; [@b21-cia-2-283]; [@b102-cia-2-283]).

In addition to increased skin thickness, estrogen has also been shown to increase the collagen content of the skin. A randomized, double-blind, placebo-controlled trial carried out by [@b103-cia-2-283] demonstrated an increase of 6.49% in skin collagen fiber content after six months of treatment with an oral combination of estrogen and cytoproterone acetate. Other authors have demonstrated an increase in overall collagen content ([@b16-cia-2-283]) and specifically collagen type III ([@b104-cia-2-283]; [@b105-cia-2-283]). Another study found no difference in skin thickness or collagen content in upper arm or abdominal skin following oral estrogen therapy ([@b43-cia-2-283]); however the patients in this study had only a short period of estrogen deficiency (median time post-menopause 12 months), which may explain this finding. Importantly, the increase in skin collagen content in response to estrogen therapy appears to be related to the initial collagen content. [@b16-cia-2-283] demonstrated that in women with low skin collagen content, estrogen is initially therapeutic, but later becomes purely prophylactic, whereas for women in the early years post-menopause with only mild collagen loss, estrogen is of prophylactic value only. Indeed, optimum collagen content was seen following two years of treatment in a study which examined the effect of estradiol implants over a period ranging from two to ten years ([@b16-cia-2-283]).

The use of topical estrogen has also been shown to increase skin collagen. [@b129-cia-2-283] demonstrated an increase in collagen content following topical estrogen administration. They also demonstrated an increase in collagen synthesis as shown by increased type I and type III procollagen levels. However, with topical administration, the effect was limited to the area to which the estrogen was directly applied ([@b129-cia-2-283]; [@b105-cia-2-283]). A more recent study examining the effect of estrogen on human skin has demonstrated an increase in collagen content in buttock skin from elderly males and females treated with topical estradiol ([@b114-cia-2-283]). Type I procollagen mRNA and protein were significantly increased in males and females, with a significantly greater increase in females compared to males. Similarly, immunohistochemical expression for type I procollagen protein was increased following estradiol treatment. The same group also demonstrated an increase in tropoelastin and fibrillin mRNA and protein in response to estradiol and suggested this can be equated to an increase in elastic fibers. Furthermore, they demonstrated an increase in TGF-β and TGF-β type II receptor mRNA and protein expression in response to estrogen therapy, although TGF-β type-I receptor expression was not increased. Since TGF-β is a growth factor known to stimulate fibroblast proliferation and extracellular matrix (ECM) secretion, they suggested that this is the mechanism by which estrogen increases ECM secretion ([@b114-cia-2-283]). Furthermore, a decrease in MMP-1 expression was demonstrated in response to topical estrogen, which may also explain increased collagen content in estrogen treated skin. Interestingly, when topical estradiol was applied to the skin of young males, similar effects were also demonstrated ([@b114-cia-2-283]).

Skin wrinkling is synonymous with aging, but is also affected by environmental and hormonal factors. It occurs due to decreased skin elasticity as a result of elastic degeneration and loss of connective tissue (reviewed in [@b106-cia-2-283]). In early postmenopausal women monitored for five years, skin elasticity has been shown to decrease by 1.5% per year, a change not seen in women on HRT ([@b49-cia-2-283]). Furthermore, conjugated equine estrogen has been shown to increase forearm skin elasticity in postmenopausal women ([@b121-cia-2-283]). [@b95-cia-2-283] demonstrated that topical estrogen thickens elastic fibers in the papillary dermis, increases their number and improves their orientation, although this effect has not been shown by other authors ([@b19-cia-2-283]). This led to the suggestion that estrogen deficiency plays a role in wrinkle formation and in a large cohort study it was shown that wrinkling is reduced in postmenopausal women administered estrogen ([@b33-cia-2-283]).

In post-menopausal women skin wrinkling has also been shown to be improved by topical estrogen therapy after a 24-week treatment period ([@b29-cia-2-283]). However, other authors have demonstrated an improvement in skin elasticity, although there was no improvement in wrinkling in smokers ([@b23-cia-2-283]). Furthermore, estrogen was not shown to consistently improve the appearance of facial skin over a five-year period, suggesting the effects may be reduced in sun-exposed skin ([@b92-cia-2-283]).

More recently, [@b136-cia-2-283] demonstrated decreased facial wrinkling and increased skin rigidity following long-term oral estrogen administration. Women who were at least five years post-menopause and had either taken oral estrogen continuously, or had never used HRT, were examined by a single blind observer who assessed wrinkle formation using an objective photographic wrinkle score and measured skin rigidity using a durometer. They demonstrated that the average wrinkle score was significantly lower in the hormone treated group. Skin rigidity was also significantly lower in the group using HRT ([@b136-cia-2-283]). This suggests that estrogen therapy has long-term benefits on skin and supports the use of early and continuous HRT in preventing detrimental skin changes ([@b78-cia-2-283]).

Although estrogen administration has been shown to have positive effects on skin by delaying or preventing skin aging manifestations ([@b18-cia-2-283]; [@b101-cia-2-283]), understanding the effects of estrogen on skin is complicated by a number of factors. Firstly, when interpreting the results of studies looking at the effects of estrogen on skin it is important to remember that few randomized trials have been carried out and that the majority of trials have been observational studies. The use of different estrogen preparations and doses with, or without, the concomitant use of progesterone or testosterone also complicates this issue. Progestagens are combined with estrogen compounds and given cyclically or continuously since estrogen therapy alone may result in endometrial hyperplasia. Estrogen monotherapy can be used following hysterectomy ([@b101-cia-2-283]). Thus, making true comparisons and judgments of the isolated effects of estrogen are difficult. Indeed, topical progesterone cream (2%) alone has been shown to increase skin elasticity and decrease wrinkling in peri- and post-menopausal women ([@b50-cia-2-283]).

Controversies surrounding the risks associated with the use of hormone therapy also complicate the issue. HRT was initially introduced to improve menopausal symptoms, reduce the risk of osteoporosis and was thought to reduce the risk of cardiovascular events ([@b116-cia-2-283]). However, a recent study has suggested that HRT may increase the risk of cardiovascular events ([@b41-cia-2-283]). It has also been reported that HRT may increase the risk of breast cancer ([@b98-cia-2-283]) and this has led to a significant reconsideration of the risks and benefits of systemic HRT. In response to this, recommendations for the use of HRT have become more stringent and it is now generally accepted that HRT should only be used to relieve menopausal symptoms, in the short-term ([@b46-cia-2-283]). This means that justifying the use of randomized clinical trials to assess the effects of systemic estrogen on skin is difficult from a risk-benefit point of view.

Despite the controversy that surrounds the use of HRT in post-menopausal women; many authors suggest that the benefits of HRT in skin necessitate the need for further studies of its effects, not only in skin, but in other organ systems ([@b32-cia-2-283]; [@b78-cia-2-283]; [@b136-cia-2-283]). Furthermore, as the visual effects that are seen in the skin following the menopause may physiologically mirror the internal effects in other tissues (bone, cardiovascular system, cancer), skin may represent an easily accessible model. The use of topical estrogen could also be considered, but again this requires further investigation to determine the optimal dose for local benefits, while ensuring that systemic effects are avoided ([@b130-cia-2-283]).

Skin and aging
==============

Although estrogen deficiency is associated with skin changes, intrinsic aging also affects skin physiology. Skin undergoes profound changes associated with aging. This is most apparent in the face and other sun-exposed areas. Aging is associated with a decrease in skin thickness due to atrophy of the epidermis, dermis and subcutaneous fat. This is associated with dryness, wrinkling and an increased incidence of proliferative lesions. In the epidermis, aging is associated with a decrease in epidermal thickness, flattening of the dermal papilla and a decrease in melanocyte and Langerhans cell density. Within the dermis, increasing age leads to reduced fibroblast activity, reduced collagen and hyaluronic acid content, more fragmented elastin fibers and decreased vascularity ([@b6-cia-2-283]). Aging skin has also been shown to have increased pro-enzyme MMP-2 expression ([@b8-cia-2-283]), suggesting that aged skin is primed for tissue breakdown. A number of environmental factors such as sun exposure and smoking also affect the rate at which skin changes.

Mechanism of estrogen action
============================

Estrogens are the terminal ligand in the biosynthetic pathway of gonadal steroid hormones and are synthesized from androgens by the loss of the C-19 angular methyl group and the formation of an aromatic A ring by the aromatase complex ([@b89-cia-2-283]). Estrone is derived from androstenedione, whereas estradiol is formed from testosterone. Estrone and estradiol are interconvertable due to different isoenzymes of 17β-hydroxysteroid dehydrogenase ([@b65-cia-2-283]).

The principle source of estrogen biosynthesis is the ovary in females of reproductive age. In men, estradiol can be produced in peripheral tissues by the actions of aromatase on testosterone ([@b108-cia-2-283]). Humans, along with some other primates are unusual in that the adrenal cortex secretes large quantities of adrenal androgens, including dehydroepiandrosterone (DHEA), which can then be converted into active steroids in peripheral tissues providing they have the appropriate enzymes ([@b65-cia-2-283]). DHEA synthesized in the adrenal zona reticularis serves as the main precursor of active estrogens in post-menopausal women. Notwithstanding, the production of DHEA also decreases with age. Serum concentrations are low prior to puberty, reaching a peak in adulthood. However, throughout adult life, levels decline and by the 7th decade are reduced to only 10%--20% of the peak concentrations in both sexes ([@b87-cia-2-283]). Therefore, with aging the precursor steroids for peripheral estrogen biosynthesis are reduced.

### Estrogen receptor: non-genomic signaling

While the best described mode of estrogen signaling is mediated via two related proteins (ERα and ERβ) that belong to the nuclear receptor superfamily (see below), a further level of complexity in estrogen signaling is now apparent due to studies demonstrating rapid effects in response to estrogens that cannot be attributed to signaling via the classical intracellular nuclear receptors and their genomic pathways ([@b67-cia-2-283]). These rapid effects, at rates much faster than can be attributed to genomic signaling, have led to the view that cell membrane forms of estrogen receptors exist that are coupled to cytosolic signal transduction proteins able to initiate different signaling cascades via conventional second messengers ([@b77-cia-2-283]). Estrogens have been shown to activate second messengers such as adenylate cyclase and cAMP ([@b3-cia-2-283]), phospholipase C ([@b68-cia-2-283]), protein kinase C ([@b71-cia-2-283]) and the mitogen-activated protein kinase (MAPK) ([@b107-cia-2-283]; [@b99-cia-2-283]). Interestingly, estrogen can also activate ligand or voltage-gated ion channels ([@b86-cia-2-283]; [@b97-cia-2-283]; [@b77-cia-2-283]) resulting in the increase in levels of intracellular calcium ([@b13-cia-2-283]).

The term "activators of nongenotropic estrogen-like signaling (ANGELS)" has been introduced to define small nonphenolic molecules that mimic the nongenotropic actions of estrogens, but lack their classical genotropic effects ([@b61-cia-2-283]). ANGELS appear to represent a novel class of compounds that differ mechanistically from classical estrogens. One such compound is estren, which is completely devoid of classical genotropic actions ([@b61-cia-2-283]), but can reverse bone loss in sex steroid-deficient mice ([@b60-cia-2-283]).

### Classical mechanism of action: genomic signaling

Two distinct intracellular estrogen receptors (ERα and ERβ) have been identified that belong to the superfamily family of nuclear hormone receptors ([@b76-cia-2-283]). It is now clear that estrogens have important effects on many non-reproductive tissues and the expression of the two estrogen receptors is tissue dependent. In addition to the male and female reproductive tissues, ERα and ERβ are expressed in tissues as diverse as bone, brain, lung, bladder, thymus, pituitary, hypothalamus, heart, kidney, adrenal, the cardiovascular system and the skin including the hair follicle (reviewed in [@b123-cia-2-283], [@b124-cia-2-283]).

The two estrogen receptors are distinct proteins encoded by separate genes that are located on different chromosomes ([@b38-cia-2-283]). The ERα and ERβ proteins share approximately 97% homology in the DNA binding domain, with only a few amino acids differing in this region. However, in the ligand binding domain they only share 59% homology ([@b42-cia-2-283]), while they share little homology in the amino terminal domain, hinge domain and COOH domain ([@b76-cia-2-283]). With such a difference in the ligand binding domain, it could be anticipated that the receptors would bind estradiol with different affinities; this however is not the case, since 17β-estradiol has a similar affinity for both receptors. Ligand binding analysis has shown an average dissociation constant of 0.5 nM for 17β-estradiol on mouse ERβ and 0.2 nM on mouse ERα ([@b40-cia-2-283]), suggesting ERβ has a slightly lower affinity for 17β-estradiol. Many synthetic estrogens also bind both receptors with a similar affinity ([@b63-cia-2-283]).

Similar to all intracellular steroid receptors, ERα and ERβ are ligand activated nuclear transcription factors that enhance target-gene transcription upon binding to chromatin. Activation of the target gene by 17β-estradiol activates both ERα and ERβ to increase transcriptional activities when dimers of the liganded receptors bind to estrogen response elements (ERE) which are specific DNA palindrome sequences located in the promoter region of estrogen-regulated target genes ([@b59-cia-2-283]). Activation of transcription also requires the recruitment of a large coactivator complex composed of p160 coactivators including GRIP1 and SRC-1 and the histone acetyltransferases p300/CREB-binding protein and pCAF ([@b134-cia-2-283]). While the DNA binding domain mediates ERE recognition, the mediation of coactivator recruitment occurs via distinct activation functions (AF) located in the N-terminal domain (AF-1) and the ligand binding domain (AF-2) ([Figure 2](#f2-cia-2-283){ref-type="fig"}). Coactivators are tissue-specific and there is some evidence that ERα and ERβ differ in their requirements for coactivators in a cell and tissue dependent manner ([@b112-cia-2-283]).

In addition to the well characterized mode of action via EREs, estrogen receptors may also interact with other transcription factors bound to their cognate DNA binding sites through protein-protein interactions. For example, both ERα and ERβ enhance the transcription of genes that contain AP-1 sites, the cognate binding site for the Jun/Fos complex ([@b85-cia-2-283]) (see [Figure 3](#f3-cia-2-283){ref-type="fig"}). ERα and ERβ can also enhance the transcription of genes that contain binding sites for other transcription factors ([@b37-cia-2-283]). While the precise mechanism of ER action at AP-1 sites is still unclear, studies suggest that there are striking differences from ER action at EREs ([@b133-cia-2-283]).

Since ERα and ERβ are often co-localized within many tissues, it was assumed that they would exert their effects on different target genes. However, there is evidence that ERα and ERβ can form both homodimers and heterodimers and that ERα homodimers and ERα/ERβ heterodimers are formed in preference to ERβ homodimers ([@b28-cia-2-283]). It has been proposed that in a cell where both estrogen receptors are present, the overall estrogen responsiveness may be determined by the ERα:ERβ ratio ([@b117-cia-2-283]). Furthermore, where ERs are binding to AP-1 sites, binding of ERα or ERβ homodimers can have opposing effects on gene transcription ([@b85-cia-2-283]; [@b64-cia-2-283]). Thus, this creates the possibility that ERα and ERβ can work antagonistically or synergistically ([@b72-cia-2-283]).

Selective estrogen receptor modulators (SERMs)
==============================================

Clinically, estrogens are widely used in the form of both oral contraceptives and HRT. Although they are highly effective both as a contraceptive and managing menopausal symptoms in women, nevertheless the use of estrogens has also been implicated as a risk factor in breast and uterine cancer ([@b98-cia-2-283]).

Tamoxifen is a non-steroidal triphenylethylene ([Figure 4](#f4-cia-2-283){ref-type="fig"}), which is widely used in the management of women with hormonally responsive early and metastatic breast cancer, since it acts as an antagonist of estrogen action in breast tissue ([@b24-cia-2-283]). Although tamoxifen blocks estrogen action in breast cancer cells, conversely it stimulates proliferation of uterine cells by acting as an estrogen agonist, thereby resulting in an increase in the risk of endometrial cancer by three fold ([@b120-cia-2-283]).

The study of the selective biological effects of tamoxifen in different tissues has led to the embodiment of the concept of selective estrogen receptor modulators or SERMs. SERMs bind to estrogen receptors and can act as either estrogen agonists or antagonists depending on the target tissue. Current SERMs generally act as agonists in liver, in bone by inhibiting bone resorption, and on the cardiovascular system by reducing the markers of cardiovascular risk such as LDL. They are often antagonists in tissues such as breast and brain, but exhibit a mixed response in the uterus ([@b54-cia-2-283]; [@b31-cia-2-283]). The undesirable uterine side-effects of tamoxifen have provided the drive for the development of the "ideal" SERM.

More recently a new SERM, raloxifene has been introduced ([Figure 4](#f4-cia-2-283){ref-type="fig"}). Raloxifene is derived from a benzothiophene series of anti-estrogens and is now approved for the prevention and treatment of osteoporosis in post-menopausal women (reviewed in [@b83-cia-2-283]). While raloxifene exhibits antiestrogen activity in the breast, in contrast to tamoxifen, it lacks uterotrophic activity and thus signifies an improved agonist/antagonist profile ([@b120-cia-2-283]).

Since the three-dimensional structure of tamoxifen and raloxifene differ to 17β-estradiol ([Figure 4](#f4-cia-2-283){ref-type="fig"}) binding of these ligands to the estrogen receptor in breast tissue results in a conformational change that blocks AF-2 activity. This results in differences in their ability to recruit essential co-activators, thus eliminating the estrogen effect ([@b115-cia-2-283]). Although tamoxifen inhibits the transcription of genes that are regulated by a classical ERE, tamoxifen activates the AP-1 target gene in uterine cells ([@b64-cia-2-283]) in an AF-independent manner. Raloxifene, however, does not have the ability to activate AP-1 which would account for the differences seen in their effects on the uterus. This gives numerous combinations by which SERMS can modulate estrogen receptors in a tissue-specific manner. Understanding why SERMs exhibit different estrogen activities will help to identity new SERMs with more favourable profiles.

Since hypoestrogenism has detrimental effects on many other tissues including the skeleton, the CNS and the cardiovascular system, many consider the ideal SERM to have estrogenic activity in bone, the cardiovascular system, vagina and CNS, yet have antiestrogenic activity in the breast and uterus. However, since neither tamoxifen nor raloxifene possess this spectrum of properties, there is clearly a market for the development of specific SERMs to address these issues.

SERMs and skin biology
======================

Despite the well documented effects of estrogen on skin physiology and aging, there is very limited data on the effect of SERMs on the skin. One of the adverse effects of tamoxifen include hot flashes and vaginal dryness (reviewed in [@b83-cia-2-283]), but there have been no studies to determine effects on skin thickness, collagen content, elastic fibers or the formation of wrinkles. A histopathological assessment of rat skin following subcutaneous administration of tamoxifen observed that tamoxifen treatment resulted in the appearance of abnormal hair follicles, epidermal atrophy and increased dermal fibrosis, particularly around the hair follicles ([@b53-cia-2-283]). There have been reports of tamoxifen treatment causing diffuse thinning of the hair with moderate receding of the frontal hair line ([@b9-cia-2-283]) and the development of alopecia on the crown, which was reversed when treatment was stopped ([@b39-cia-2-283]). Although alopecia is reported on the data and patient information sheet for proprietary tamoxifen, alopecia is not reported in the datasheets for the generic form of tamoxifen ([@b39-cia-2-283]).

We have recently reported that tamoxifen alone has no effect on human hair shaft elongation in organ culture, suggesting it is not an estrogen agonist ([@b81-cia-2-283]). However, a 10-fold excess of tamoxifen incubated in combination with 17β-estradiol eliminated the inhibitory effect of 17β-estradiol, suggesting that tamoxifen acts as an antagonist of estrogen in the female scalp hair follicle ([@b81-cia-2-283]).

Notwithstanding, there have been some studies that suggest tamoxifen may be useful in the treatment of keloids. Tamoxifen has been shown to inhibit the proliferation of fibroblasts cultured from keloid biopsies, and to inhibit their contraction ([@b52-cia-2-283]). Keloid dermal fibroblasts have also been shown to secrete higher levels of TGF-β1 than fetal dermal fibroblasts, which can be counteracted by incubation with tamoxifen ([@b73-cia-2-283]).

Together these provide evidence that tamoxifen may improve wound healing and improve dermal scarring. Cell migration is a key element of the wound healing process and a recent study has shown that estrogen and tamoxifen induce cytoskeleton remodeling and migration in endometrial cancer cells ([@b1-cia-2-283]). Another fundamental aspect of cutaneous wound healing is an increase in dermal fibroblast proliferation, and recent studies in our laboratory have shown that monolayers of human dermal fibroblasts that have been mechanically wounded in vitro demonstrate a significantly increased rate of both migration and proliferation in response to 17β-estradiol ([@b118-cia-2-283]). Furthermore, we have recently demonstrated that the proliferative activity of mechanically wounded cultured human dermal fibroblasts is significantly increased in the presence of tamoxifen and raloxifene ([Figure 5](#f5-cia-2-283){ref-type="fig"}), supporting the application of SERMs as potential therapeutic agents to improve wound healing.

Other groups using cultured human dermal fibroblasts have shown that the levels of expression of ERα and ERβ can be modulated by 17β-estradiol, tamoxifen and raloxifene ([@b45-cia-2-283]). Another study has shown that raloxfine has a stronger positive stimulatory effect on collagen biosynthesis than 17β-estradiol ([@b122-cia-2-283]) and that in contrast to estradiol, raloxifene inhibits the expression of MMP-9. Tamoxifen has been used in clinical trials for patients with melanoma since the late 1970s. Initially it showed promise as a single agent and then was combined with chemotherapy in 1984 ([@b100-cia-2-283]). Since then, a number of phase II clinical trials have combined tamoxifen with different chemotherapeutic agents with overall response rates ranging from 8% to 60%. However, treatment of melanoma with tamoxifen still remains controversial, since it is still unclear whether the strength of evidence from the randomized trials outweighs the combined evidence from numerous nonrandomized trials ([@b100-cia-2-283]).

In vitro, tamoxifen has also been shown to inhibit the proliferation of a melanoma cell line (SK-Mel--28) (Lama et al 1999). Cell attachment to plastic and invasion through fibronection in vitro of the highly metastatic cutaneous melanoma cell line (A375-SM) is also reduced in the presence of tamoxifen ([@b30-cia-2-283]). Others have shown that tamoxifen can induce cell death in malignant melanoma cell lines and this cytoxicity may be due to inactivation of the insulin-like growth factor receptor (IGF-1R) (Kanter-Lewensohn et al 1999). Clearly, malignant melanomas and the derived cell lines may be heterogeneous and the actions of estrogens in these tissues is worthy of further study.

Potential SERMs in development
==============================

Recently much emphasis has been placed on developing SERMS, which have tissue specific estrogen actions that can separate the positive biological effects from the undesirable ones. Several SERM trials are underway but are being evaluated in terms of traditional outcomes such as bone mineral density, breast and endometrial cancer, and cardiovascular risk. A number of compounds are currently undergoing Phase III clinical trials (<http://www.clinicaltrials.gov>). These include lasofoxifene (Pfizer), arzoxifene (Lilly) and bazedoxifene (Wyeth) (see [Figure 6](#f6-cia-2-283){ref-type="fig"}).

The safety and effectiveness of lasofoxifene in reducing new spinal fractures in women with osteoporosis is currently being investigated; (PEARL: Postmenopausal Evaluation And Risk-Reduction with Lasofoxifene). This study is expected to enroll 7500 women and the primary outcomes will investigate new radiographic vertebral fractures at 3 years, while the secondary outcomes will compare clinical fractures, non-vertebral fractures, bone mineral density, breast cancer, cardiovascular events, and gynecological safety events at 3 years.

Eli Lilly and Company is sponsoring a study of another SERM, arzoxifene, in a phase III clinical trial to determine its effects on bone mass and the uterus of postmenopausal women. This study will determine the effects of arzoxifene on bone mineral density at the spine and hip as well as the effects on the uterus. Secondary outcomes will include the effects of arzoxifene on blood tests that measure changes in bone rebuilding in postmenopausal women with low bone density; also the effects on blood lipids and other blood markers of heart disease and effects on breast density will be determined.

A third SERM in phase III clinical trial sponsored by Wyeth is bazedoxifene. The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective in the treatment of moderate to severe vasomotor symptoms associated with menopause and whether they are effective in the treatment of vaginal atrophy. The effectiveness of bazedoxifene/conjugated estrogens combinations for the prevention of endometrial hyperplasia and osteoporosis in postmenopausal women is also under investigation. However, none of these studies have been designed to assess the effects of these SERMs in the skin and it's appendages in the women studied.

Conclusion
==========

Evident changes associated with skin aging are thinning of the skin, increased dryness and reduced vascularity. The protective function of the skin can become impaired and aging is also associated with impaired wound healing, hair loss and skin cancer. Clearly the skin is an important estrogen target tissue, yet we still do not fully understand the molecular processes involved and the mechanisms by which estrogens and related compounds regulate skin function and delay skin aging. The widespread and constant expression of estrogen receptors in human skin may provide protection for the skin and its appendages, which are continuously exposed to oxidative damage due to UVB radiation.

However, the mechanisms of estrogen signaling are complex and intricate, involving multiple signaling pathways. There are at least three different receptors that may act independently, synergistically, or have opposing actions. Gene transcription also requires specialized co-activators, which are tissue and cell specific. A class of compounds that demonstrate estrogenic activity in some tissues conversely act as estrogen antagonists in other tissues. This has led to the embodiment of the term selective estrogen receptor modulators (SERMs). With the development of new generation SERMs to prevent osteoporosis and reduce the incidence of cardiovascular disease in postmenopausal women, it is important to understand their effects on the skin and the hair follicle.

Undesirable effects on the skin may lead to chronic wound healing or an increased incidence of skin cancer; in addition women find the adverse occurrence of hair loss very distressing. Conversely, there may be SERMs currently in use or in development that may act as estrogen agonists in human skin and the hair follicle and may potentially provide a useful therapy for clinical application to delay the aging manifestations of the skin. However, research into the potential use of SERMs as a therapy for symptoms of skin aging appears to be very much in its infancy.

In order to understand more comprehensively the mechanism of estrogen action on skin aging, we need to improve our understanding of the complex interactions of estrogen signaling pathways. In addition to SERMs, new advances in the development of selective ligands for ERα and ERβ, and activators of nongenotrophic estrogen-like signaling (ANGELS) may also provide a basis for further interventions in pathological processes that involve the impairment of estrogen action in human skin. This may have important implications for therapies for skin aging, hair growth, skin cancer and wound healing.

We are indebted to the following for their help and encouragement relating to various aspects of this article, Professor David Sharpe, Dr Louisa Nelson and Dr Ian Laing.
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![The expression of ERα and ERβ in human epidermal keratinocytes cultured from human female breast skin. Both nuclear and cytoplasmic expression of ERα and ERβ, with intense staining in the perinuclear region was seen in epidermal keratinocytes derived from female breast skin.](cia-2-283f1){#f1-cia-2-283}

![Schematic representation of the modular structures of ERα and ERβ The modular structure of the two estrogen receptors (ERα and ERβ) illustrating several distinct functional domains. The numbers within the ERα domains represent the percentage homology between the two receptors. There is little homology between activation function-1 (AF-1) in the N-terminal domain, whereas the core sequences of AF-2 in the ligand binding domain (LBD) are identical. The numbers above each receptor represent the amino acid position of each boundary. The DNA binding domain (DBD) shows the greatest degree of homology.](cia-2-283f2){#f2-cia-2-283}

![Models of estrogen action at a classical estrogen response element (ERE) and an ER-dependent AP-1 response element. The stars represent the ligand bound to the estrogen receptor (ER). In the classical mode of action activated ERs bind as dimers to the ERE which is comprised of 2 inverted hexanucleotide repeats, and activates gene transcription. In a different mode of action, the ligand activated ER can mediate gene transcription via an AP-1 enhancer element that requires the AP-1 transcription factors Fos and Jun for transcriptional activation. The difference between the actions of the SERMs tamoxifen and raloxifene are due to their ability/inability to activate these pathways. Tamoxifen inhibits the transcription of genes regulated by the classical ERE, but activates the transcription of genes regulated by an AP-1 element. In contrast raloxifene does not have the ability to activate AP-1. Therefore there are numerous combinations by which SERMS can modulate the estrogen receptor in a tissue-specific manner.](cia-2-283f3){#f3-cia-2-283}

![Molecular structure of 17β-estradiol, tamoxifene and raloxifene.](cia-2-283f4){#f4-cia-2-283}

![Tamoxifen and raloxifene increase the DNA synthesis of mechanically wounded human dermal fibroblasts in vitro. A ^3^H-thymidine assay was used to measure DNA synthesis in wounded dermal fibroblasts (n = 3) in the presence of 100 nM tamoxifen (black bar) and 100 nM raloxifene (white bar) and vehicle control (0.0001% absolute ethanol (hatched bar). All assays were performed in triplicate dishes. Data are presented as patient mean +/-- SEM. \* p \< 0.05.](cia-2-283f5){#f5-cia-2-283}

![Molecular structure of SERMs in phase III clinical trials.](cia-2-283f6){#f6-cia-2-283}
